Women's Health is attracting more scientific and investment interest than it has in years. But many conditions are still managed symptomatically rather than treated at the level of underlying biology.
In the latest Optimum Perspectives podcast, three biotech leaders and a seasoned healthcare investor discuss what is genuinely changing across the field, from the shift towards disease-modifying science, to the challenge of building a commercial case in first-in-disease therapeutics.
Hosted by Isabelle Abdou, the episode features Colleen Acosta, CEO of Freya Biosciences; Agnès Arbat, CEO of Oriva Therapeutics; Jean Marie Duvall, CEO of ReproNovo; and Hakan Goker, Managing Director at M Ventures.
They also discuss male-factor infertility, a contributor in around half of all cases yet with strikingly few therapeutic options – and whether the \"women's health\" label still drives much-needed visibility, or risks framing as a niche something that affects a majority of the population.
🎧 Listen to the full episode here: www.optimumcomms.com/podcast/
","author_name":"Optimum Strategic Communications"}